Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suxiao Jiuxin Pill for Prevention of Acute Mountain Sickness
NCT06531161Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, randomised, double-blind trial in acute mountain sickness (AMS) comparing Suxiao Jiuxin Pill with Placebo (2 arms). Primary endpoint: Incidence rate of Acute Mountain Sickness. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
Suxiao Jiuxin Pills
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on NCT06531161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531161.